LGND News and Press, Ligand Pharmaceuticals Incorporated From 02/17/22

Ligand Pharmaceuticals Incorporated (LGND) Q4 2021 Earnings Conference Call February 17, 2022 04:30 PM ET Company Participants Simon Latimer - Head of Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Chief Financial Officer Matt Foehr - Chief Operating Officer Confer...

Ligand Pharmaceuticals press release (NASDAQ:LGND): Q4 Non-GAAP EPS of $1.80 beats by $0.43. Revenue of $72.5M (+3.6% Y/Y) beats by $7.41M. As of December 31, 2021, Ligand had cash, cash equivalents and short-term investments of $341.1 million. 2022 Financial Guidance: Ligand expects 2022 roy...

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2021, and provided an operating forecast and business updates. Ligand management will...

Review of Bumbershoot Holdings LP 2021 performance. Overview of the fund's long/short portfolio and investment positioning. Economic and investment outlook for the year ahead. For further details see: Bumbershoot Holdings - 2021 Investor Letter

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report fourth quarter 2021 financial results after the close of the U.S. financial markets on Thursday, February 17, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call w...

Sugemalimab was discovered using the OmniAb platform Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner CStone Pharmaceuticals (HKEX: 2616) has received approval from China’s National Medical Products Administration (NMPA) for suge...

Ligand Pharmaceuticals (NASDAQ:LGND) and GlaxoSmithKline (NYSE:GSK) expand an existing collaboration and license agreement. Under this, LGND will receive an upfront payment of $10M and is eligible for development and regulatory milestones up to $67.5M in addition to the payments under the ori...

Ligand to receive an upfront payment of $10 million Further leverages the Icagen ion-channel discovery technology to target neurological diseases Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today the expansion of an existing collaboration and lic...

COLUMBUS, Ohio, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that the company, in collaboration w...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...